Instrument Inactif

Autres langues Interpace Biosciences, Inc. Other OTC

Actions

IDXG

US46062X3035

Installations et services en soins de santé

Autres langues

12/05	Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
12/05	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
30/03	Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
30/03	Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
20/01	Interpace Biosciences Announces Preliminary and Unaudited Revenue Results for the Year 2025
20/01	Interpace Biosciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Full Year of 2025 and Initiates Revenue Guidance for the Full Year of 2026
20/01	Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
03/12	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
03/12	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
12/11	Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
12/11	Interpace Biosciences Q3 revenue down
12/11	Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
16/09/25	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association Annual Meeting
15/09/25	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
07/08/25	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
07/08/25	Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results
08/05/25	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
08/05/25	Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
08/05/25	Interpace Biosciences, Inc. Provides Revenue Guidance for the Full-Year 2025
24/04/25	Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
31/03/25	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
03/02/25	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
31/01/25	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
27/01/25	PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
10/01/25	Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk